However, to our knowledge, only three other publications have so far focused on tolerability and the toxicity profile in patients with DPYD deficiency receiving 5‐FU in a combined chemoradiotherapy regimen [21–23]. The gene discussed is DPYD; the disease is hyperinsulinemic hypoglycemia, familial, 4.